He Y J, Liu Z H, Hou J L
Institute of Hepatology, Southern Medical University, Guangzhou 510515, China.
Zhonghua Gan Zang Bing Za Zhi. 2018 Mar 20;26(3):169-172. doi: 10.3760/cma.j.issn.1007-3418.2018.03.002.
The elimination of hepatitis C virus(HCV) infection is still a long way to go. Direct-acting antiviral agents (DAAs) can make HCV completely cured by targeting various stages of its replication life cycle and meanwhile standardize and simplify the treatment. However, those relative factors may affect efficacy and safety should be considered by specialties in choosing the suitable regimens. Therefore, this article reviews various aspects of DAAs including development history, factors correlated with efficacy and safety, therapeutic regimens domestic listed and approved.
丙型肝炎病毒(HCV)感染的消除之路仍漫长。直接抗病毒药物(DAAs)可通过针对HCV复制生命周期的各个阶段实现完全治愈,同时规范并简化治疗。然而,专科医生在选择合适治疗方案时应考虑那些可能影响疗效和安全性的相关因素。因此,本文综述了DAAs的各个方面,包括发展历程、与疗效和安全性相关的因素、国内上市及获批的治疗方案。